Antitumor effect of fibrin glue containing temozolomide against malignant glioma

Cancer Science

Volumn 105, Issue 5, 2014, Pages 583-591

  Anai, Shigeo ^a   Hide, Takuichiro ^a   Takezaki, Tatsuya ^a   Kuroda, Jun ichiro ^a   Shinojima, Naoki ^a   Makino, Keishi ^a   Nakamura, Hideo ^a   Yano, Shigetoshi ^a   Kuratsu, Jun ichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Drug delivery system; Fibrin glue; Glioblastoma; Malignant glioma; Temozolomide

Indexed keywords

CASPASE 3; FIBRIN GLUE; KI 67 ANTIGEN; PROTEIN P16; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL DENSITY; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEMYELINATION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SENESCENCE; SUSTAINED DRUG RELEASE; TUMOR VOLUME; WEIGHT REDUCTION; WESTERN BLOTTING;

DRUG DELIVERY SYSTEM; FIBRIN GLUE; GLIOBLASTOMA; MALIGNANT GLIOMA; TEMOZOLOMIDE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; AUTOPHAGY; BRAIN NEOPLASMS; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DACARBAZINE; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; FEMALE; FIBRIN TISSUE ADHESIVE; GLIOMA; MICE; MICE, INBRED ICR; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION;

EID: 84899934324     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12397     Document Type: Article

References (36)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012; 14(Suppl. 5): v1-49.
2. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
3. Lawrence YR, Mishra MV, Werner-Wasik M et al. Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer 2012; 118: 4228-34.
4. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007; 6: 1079-99.
5. Caporali S, Falcinelli S, Starace G et al. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol 2004; 66: 478-91.
6. Ochs K, Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 2000; 60: 5815-24.
7. Knizhnik AV, Roos WP, Nikolova T et al. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS ONE 2013; 8: e55665.
8. Spotnitz WD. Commercial fibrin sealants in surgical care. Am J Surg 2001; 182: 8S-14S.
9. de Vries J, Menovsky T, van Gulik S, Wesseling P. Histological effects of fibrin glue on nervous tissue: a safety study in rats. Surg Neurol 2002; 57: 415-22 discussion 22.
10. Kassam A, Nemoto E, Balzer J et al. Effects of Tisseel fibrin glue on the central nervous system of nonhuman primates. Ear Nose Throat J 2004; 83: 246-8, 50, 52 passim.
11. Yasuda H, Kuroda S, Nanba R et al. A novel coating biomaterial for intracranial aneurysms: effects and safety in extra- and intracranial carotid artery. Neuropathology 2005; 25: 66-76.
12. Spicer PP, Mikos AG. Fibrin glue as a drug delivery system. J Controlled Release 2010; 148: 49-55.
13. Wick W, Stupp R, Beule AC et al. A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro Oncol 2008; 10: 1019-24.
14. Balenci L, Clarke ID, Dirks PB et al. IQGAP1 protein specifies amplifying cancer cells in glioblastoma multiforme. Cancer Res 2006; 66: 9074-82.
15. Kim H, Likhari P, Parker D et al. High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. J Pharm Biomed Anal 2001; 24: 461-8.
16. Jensen MM, Jorgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging 2008; 8: 16.
17. Shinojima N, Tada K, Shiraishi S et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003; 63: 6962-70.
18. Muta D, Makino K, Nakamura H, Yano S, Kudo M, Kuratsu J. Inhibition of eIF4E phosphorylation reduces cell growth and proliferation in primary central nervous system lymphoma cells. J Neurooncol 2011; 101: 33-9.
19. Houghton PJ, Stewart CF, Cheshire PJ et al. Antitumor activity of temozolomide combined with irinotecan is partly independent of O-6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 2000; 6: 4110-8.
20. Middlemas DS, Stewart CF, Kirstein MN et al. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 2000; 6: 998-1007.
21. Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995; 345: 1008-12.
22. Westphal M, Hilt DC, Bortey E et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003; 5: 79-88.
23. McGirt MJ, Than KD, Weingart JD et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009; 110: 583-8.
24. Noel G, Schott R, Froelich S et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys 2012; 82: 749-55.
25. Ostermann S, Csajka C, Buclin T et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004; 10: 3728-36.
26. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004; 11: 448-57.
27. Filippi-Chiela EC, Thome MP, Bueno ESMM et al. Resveratrol abrogates the Temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the Temozolomide-induced senescence in glioma cells. BMC Cancer 2013; 13: 147.
28. Hirose Y, Katayama M, Mirzoeva OK, Berger MS, Pieper RO. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res 2005; 65: 4861-9.
29. Brada M, Judson I, Beale P et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999; 81: 1022-30.
30. Yung WK, Prados MD, Yaya-Tur R et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999; 17: 2762-71.
31. Norregaard A, Jensen SS, Kolenda J et al. Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers. Neurotox Res 2012; 22: 43-58.
32. Andrasi M, Bustos R, Gaspar A, Gomez FA, Klekner A. Analysis and stability study of temozolomide using capillary electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1801-8.
33. Beale P, Judson I, Moore S et al. Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. Cancer Chemother Pharmacol 1999; 44: 389-94.
34. Yoshida H, Yamaoka Y, Shinoyama M, Kamiya A. Novel drug delivery system using autologous fibrin glue-release properties of anti-cancer drugs. Biol Pharm Bull 2000; 23: 371-4.
35. Kim HK, Lin CC, Parker D et al. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. J Chromatogr B Biomed Sci Appl 1997; 703: 225-33.
36. Shen F, Decosterd LA, Gander M, Leyvraz S, Biollax J, Lejeune F. Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Biomed Appl 1995; 667: 291-300.